CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  Lymphoma
  
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those agents in clinical practice.
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and relapsed/refractory (R/R) Hodgkin lymphoma.
  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Consider patient age, performance status and other clinical and biological factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor (CAR) T-cell therapy for R/R DLBCL, FL and MCL, and counsel appropriately selected patients about the potential benefits of this therapeutic strategy.
  • Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in clinical management.
  • Recall new data with agents and strategies currently under investigation for various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.
  Urothelial Bladder Cancer and Renal Cell Carcinoma
  
  • Review available clinical trial results with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic urothelial bladder cancer (UBC), and determine the current utility of these agents in clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate.
  • Effectively apply evidence-based research and other clinical and biological factors in the best-practice selection of first-line therapy for patients with metastatic renal cell carcinoma (RCC).
  • Develop a rational approach to the selection and sequencing of systemic therapies for patients with metastatic RCC who experience disease progression on first-line treatment.
  • Consider available data supporting the use of anti-PD-1 antibody therapy for nonmetastatic UBC and RCC, and determine how this strategy can be appropriately integrated into patient care.
  • Reflect on available and emerging data with investigational agents and strategies currently in testing for UBC and RCC, and appropriately refer patients for clinical trial participation.
  Hepatobiliary and Pancreatic Cancers
  
  • Consider age, performance status, degree of liver function and other clinical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.
  • Evaluate available data documenting the efficacy and safety of anti-PD-L1 antibody therapy in combination with chemotherapy as first-line treatment for advanced biliary tract cancers (BTCs), and consider the clinical role of this strategy.
  • Recognize the molecular heterogeneity of cholangiocarcinoma and other BTCs, and appreciate the biological rationale for efforts to exploit documented alterations in patients with these diseases.
  • Recall clinical trial data with approved and investigational systemic interventions for patients with metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to selecting therapy.
  • Appraise available and emerging data with investigational agents currently in testing for pancreatic and hepatobiliary cancers, and appropriately refer patients for clinical trial participation.
  Gynecologic Cancers
  
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for newly diagnosed and recurrent ovarian cancer (OC), and use this information to optimally incorporate these agents into patient care.
  • Appreciate the biological rationale for and published and emerging clinical research data with PARP inhibitors in combination with other systemic therapies, and consider the current and potential implications for OC management.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal testing methods and the current role of novel approaches to therapeutically exploit this newly relevant biomarker.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies for advanced microsatellite instability-high or mismatch repair-deficient endometrial cancer (EC), and appropriately integrate these agents into patient care.
  • Consider the biological rationale for and available and emerging data with the combination of anti-PD-1/PD-L1 antibodies with chemotherapy and/or other systemic agents, and select patients with advanced EC for treatment with these novel regimens.
  • Comprehend published efficacy and safety findings with anti-PD-1 antibodies as monotherapy or in combination with chemotherapy with and without anti-VEGF therapy for metastatic cervical cancer (CC), and consider the current and potential clinical role of immune checkpoint inhibition.
  • Recognize the incidence of tissue factor expression in patients with CC, and evaluate the current and future role of novel agents designed to exploit this therapeutic target.
  • Reflect on investigational agents and strategies currently in testing for OC, EC and CC, and appropriately refer patients for clinical trial participation.
  Multiple Myeloma
  
  • Customize the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM), considering new clinical research findings, patient- and disease-related factors — including cytogenetic profile — and fitness for stem cell transplantation.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with R/R MM.
  • Understand the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies in order to facilitate their integration into MM management algorithms.
  • Evaluate the biological rationale for the use of CAR T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted strategy for MM, and identify patients for whom this novel approach should be considered or recommended.
  • Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and select patients for whom treatment with or a clinical trial of one of these novel agents would be appropriate.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for MM, and counsel appropriate patients about availability and participation.
  HER2-Positive and Triple-Negative Breast Cancer
  
  • Evaluate recently presented clinical research findings to determine their effect on the current management of localized or metastatic HER2-positive or triple-negative breast cancer.
  • Use published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Review published clinical trial data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies and PARP inhibitors for patients with localized or metastatic triple-negative breast cancer (TNBC), and use this information to make appropriate treatment recommendations.
  • Implement a long-term clinical care plan for patients with metastatic HER2-positive breast cancer, incorporating current and recently approved anti-HER2 therapies.
  • Evaluate published research guiding the selection and sequencing of available therapeutic agents for patients with metastatic TNBC.
  • Appreciate the incidence, characteristics and clinical relevance of HER2-low metastatic breast cancer, and understand available disease-management approaches.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and strategies under development for localized and metastatic HER2-positive or triple-negative breast cancer.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 6.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AON23/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Mitesh J Borad, MD
  Professor of Medicine
  Mayo Clinic College of Medicine and Science
  Program Leader, Gene and Virus Therapy Program
  Mayo Clinic Comprehensive Cancer Center
  Director, Precision Cancer Therapeutics Cancer Program
  Mayo Clinic Center for Individualized Medicine
  Scottsdale, Arizona
  
  Advisory Committee: Cadila Pharmaceuticals, Compass Therapeutics, Diffusion Pharmaceuticals, Eisai Inc, Elevar Therapeutics, Exelixis Inc, Imugene, Imvax Inc, Jazz Pharmaceuticals Inc, KaliVir Immunotherapeutics, Kriya Therapeutics, Merck, OncoMyx Therapeutics, Revolution Medicines, Tempus, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Biond Biologics, Compass Therapeutics, Dragonfly Therapeutics, HiFiBiO Therapeutics, JSI Bio, Quaint Pharmaceuticals, Servier Pharmaceuticals LLC, Turnstone Biologics, ZielBio; Stock Options/Ownership — Public Company: Abeona Therapeutics, ADC Therapeutics, Assertio, bluebird bio, Homology Medicines Inc, Intercept Pharmaceuticals Inc; Nonrelevant Financial Relationship: George Clinical.
  
  Anthony El-Khoueiry, MD
  Associate Professor of Medicine
  Associate Director for Clinical Research
  Phase I Program Director
  USC Norris Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Qurient, Senti Bio, Tallac Therapeutics; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Auransa Inc, Fulgent.
  
  Christopher R Flowers, MD, MS
  Chair ad Interim, Division of Cancer Medicine
  Professor, Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, N-Power Medicine Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Stock Options – Private Company: Foresight Diagnostics, N-Power Medicine Inc; Nonrelevant Financial Relationship: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation.
  
  Sara A Hurvitz, MD, FACP
  Professor
  Senior Vice President
  Clinical Research Division
  Fred Hutchinson Cancer Center
  Head, Division of Hematology/Oncology
  UW Medicine
  Seattle, Washington
  
  Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc.
  
  Thomas E Hutson, DO, PharmD
  Director, GU Oncology Program
  Co-Director, Urologic Cancer Research and Treatment Center
  Texas Oncology
  Charles A Sammons Cancer Center
  Baylor University Medical Center
  Professor of Medicine
  Texas A&M HSC College of Medicine
  Dallas, Texas
  
  Consulting Speaker and Research Support: AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc.
  
  Amrita Krishnan, MD
  Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research
  Professor of Hematology/Hematopoietic Cell Transplantation
  City of Hope Cancer Center
  Duarte, California
  
  Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Janssen Biotech Inc; Speakers Bureau: Bristol Myers Squibb, Takeda Pharmaceuticals USA Inc; Stock Options/Ownership — Public Company: Bristol Myers Squibb.
  
  Ann S LaCasce, MD, MMSc
  Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
  Associate Professor of Medicine, Harvard Medical School
  Lymphoma Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Kite, A Gilead Company, Seagen Inc; Data and Safety Monitoring Board/Committee (Does Not Take Payment): Bristol Myers Squibb.
  
  Heather McArthur, MD, MPH
  Associate Professor, Department of Internal Medicine
  Clinical Director, Breast Cancer Program
  Komen Distinguished Chair in Clinical Breast Cancer Research
  UT Southwestern Medical Center
  Dallas, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck; Nonrelevant Financial Relationship: Crown Bioscience.
  
  Bradley J Monk, MD
  Professor
  Division of Gynecologic Oncology
  University of Arizona College of Medicine
  Creighton University School of Medicine
  Phoenix, Arizona
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Myriad Genetic Laboratories Inc, Novocure Inc, Seagen Inc, Tesaro, A GSK Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Myriad Genetic Laboratories Inc, Tesaro, A GSK Company.
  
  Kathleen N Moore, MD, MS
  Associate Director, Clinical Research
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Director, TSET Phase I Drug Unit
  Co-Director, Cancer Therapeutics Program
  Stephenson Cancer Center at the University of Oklahoma HSC
  Associate Director, GOG Partners
  Board of Directors, GOG Foundation
  Oklahoma City, Oklahoma
  
  Advisory Committee: Aadi Bioscience, Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, InxMed, Iovance Biotherapeutics, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, PTC Therapeutics, Regeneron Pharmaceuticals Inc, Verastem Inc; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, DualityBio, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, GSK, Lilly, Merck, PTC Therapeutics, Verastem Inc.
  
  Robert Z Orlowski, MD, PhD
  Florence Maude Thomas Cancer Research Professor
  Department of Lymphoma and Myeloma
  Professor, Department of Experimental Therapeutics
  Director, Myeloma Section
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, BioTheryX Inc, Bristol Myers Squibb, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Nanjing IASO Biotherapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Clinical Research Funding: Bristol Myers Squibb, CARsgen Therapeutics, Exelixis Inc, Heidelberg Pharma, Janssen Biotech Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, BioTheryX Inc, Heidelberg Pharma; Patents: Asylia Therapeutics Inc.
  
  Guru P Sonpavde, MD
  Director of Genitourinary Medical Oncology and Phase I Clinical Research
  Christopher K Glanz Chair for Bladder Cancer Research
  AdventHealth Cancer Institute
  Professor of Medicine, University of Central Florida
  Orlando, Florida
  
  Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Bristol Myers Squibb, EMD Serono Inc, G1 Therapeutics Inc, Gilead Sciences Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lucence, Merck, Pfizer Inc, Scholar Rock, Seagen Inc, Tempus; Consulting Agreements: Merck, Servier Pharmaceuticals LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Gilead Sciences Inc, Helsinn Healthcare SA, Jazz Pharmaceuticals Inc, Lucence, Sanofi; Data and Safety Monitoring Board/Committee: Mereo BioPharma; Speakers Bureau: Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Gilead Sciences Inc, Janssen Biotech Inc, Natera Inc, Seagen Inc; Nonrelevant Financial Relationship: Informação Brasileira de Oncologia Ltda, Myriad Genetic Laboratories Inc (spouse employment), Onviv, PracticeUpdate, PrecisCa, Primum, Syapse, UptoDate, Vial.
  
  CO-MODERATOR
  Stephen "Fred" Divers, MD
  Chief Medical Officer
  American Oncology Network
  Hot Springs, Arkansas
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Daiichi Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Merck, Regeneron Pharmaceuticals Inc, R-Pharm US, Seagen Inc, and Taiho Oncology Inc.
  
  Release date: November 2023
  Expiration date: November 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.